Bristol Myers Squibb disclosed a previously unreported patient death in its multiple sclerosis CAR-T trial, Breakfree-2, involving its zola-cel therapy, after earlier reports of fatal events in a competitor trial. The event was described as a fatal episode of septic pneumonia occurring the day after high-dose cyclophosphamide and late-onset motor symptoms. BMS said zola-cel’s causal role remains undetermined, citing that the patient’s late-onset symptoms, extensive pretreatment, and additional complications confounded attribution. The company emphasized that the death was outside the prior data cutoff and that it initiated a full case review with investigators, regulatory authorities, and its safety review committee. Across all zola-cel programs, BMS reported this as the only Grade 5 event observed, with just under half of trial patients experiencing cytokine release syndrome. The disclosure matters for CAR-T risk management, monitoring protocols, and patient counseling. Clinicians will likely scrutinize how late-onset neurologic changes and infection risk co-tracked in this case narrative, and whether response mitigation strategies require refinement.